BioTuesdays

Category - Markets

Theratechnologies
Markets

CIBC starts Theratechnologies at OP

CIBC World Markets initiated coverage of Theratechnologies (TSX:TH) with an “outperform” rating and $10 price target. The stock closed at $5.95 on April 19. Theratechnologies has a focused strategy and business plan to...

April 20, 2017
ImmunoGen
Markets

Leerink ups Immunogen to OP from MP

Leerink upgraded Immunogen (NASDAQ:IMGN) to “outperform” from “market perform” and raised its price target to $8 from $2 based on a “higher level of conviction” on lead asset, mirvetuximab soravtansine, providing an...

April 19, 2017
Quotient
Markets

BTIG starts Quotient at buy

BTIG initiated coverage of Quotient (NASDAQ:QTNT) with a “buy” rating and $22 price target. The stock closed at $6.26 on April 17. British-based Quotient develops and commercializes tests for blood grouping and...

April 18, 2017
Bellerophon Therapeutics
Markets

Ladenburg starts Bellerophon at buy

Ladenburg Thalmann initiated coverage of Bellerophon Therapeutics (NASDAQ:BLPH) with a “buy” rating and 12-month price target of $4.50. The stock closed at $1.18 on April 13. Bellerophon is developing and optimizing...

April 17, 2017
Reata Pharma
Markets

Ladenburg starts Reata at buy

Ladenburg Thalmann launched coverage of Reata Pharmaceuticals (NASDAQ:RETA) with a “buy” rating and price target of $55. The stock closed at $21.21 on April 12. Reata focuses on development of small molecule drugs for...

April 13, 2017
Auris Medical
Markets

Roth starts Auris Medical at buy

Roth Capital Partners initiated coverage of Auris Medical Holding (NASDAQ:EARS), a Swiss biopharmaceutical company developing therapeutics that address unmet medical needs in otology, with a “buy” rating and price...

April 13, 2017
Cidara Therapeutics Logo
Markets

Ladenburg starts Cidara at buy

Ladenburg Thalmann launched coverage of Cidara Therapeutics (NASDAQ:CDTX) with a “buy” rating and $11.25 price target. The stock closed at $6.95 on March 11. “We view Cidara as a balanced portfolio of infectious disease...

April 12, 2017
Akari Therapeutics Logo
Markets

WB starts Akari Therapeutics at OP

William Blair launched coverage of Akari Therapeutics (NASDAQ:AKTX) with an “outperform” rating. The stock closed at $11.62 on April 5. Akari is focused on the development of next-generation complement inhibitors for...

April 6, 2017
Markets

HCW ups SteadyMed price target to $15

H.C. Wainwright raised its price target for SteadyMed (NASDAQ:STDY) to $15 from $10 after the Patent Trial and Appeal Board ruled in favor of SteadyMed in an inter partes review (IPR) proceeding against United...

April 3, 2017
Calithera Biosciences
Markets

Leerink resumes coverage of Calithera at OP

Leerink resumed coverage of Calithera Biosciences (NASDAQ:CALA) with an “outperform” rating and a $16 price target, saying the company is well positioned to execute with multiple sources of upside. The stock closed at...

April 3, 2017